Industry sources indicate that GE HealthCare Technologies Inc (NASDAQ: GEHC) is in deep negotiations to purchase Sofie Biosciences for approximately $1 billion, a move set to broaden its footprint in the production of radioactive diagnostic agents utilized in medical imaging. A potential agreement between the entities could be unveiled as early as this week, though discussions remain fluid and may still collapse.
Sofie specializes in developing radiopharmaceuticals and manages a distribution network dedicated to creating short-lived radioactive substances essential for positron emission tomography (PET). Its pipeline features diagnostic agents designed to identify specific gastric-esophageal and pancreatic cancers. Acquiring Sofie would bolster GE HealthCare's pharmaceutical diagnostics arm, which supplies agents administered to patients prior to imaging procedures. This deal would also solidify the company's position in a rapidly expanding niche that merges specialized drugs with the scanning equipment GE HealthCare already markets.
By offering both imaging systems and the accompanying diagnostic compounds, this acquisition could enable GE HealthCare to derive greater revenue from each scan conducted. Unlike bulky imaging machinery, which hospitals purchase infrequently, radiopharmaceuticals present a more consistent recurring income stream. For investors, the critical concerns center on whether the price tag proves justified and how swiftly Sofie can transition its developmental projects into commercially significant revenue.
Should the deal materialize, it would represent GE HealthCare's second major acquisition since its separation from General Electric in January 2023. Since its market debut, the company's stock has appreciated roughly 12%, trailing the considerably stronger performance of former GE counterparts GE Vernova Inc (NYSE: GEV) and GE Aerospace (NYSE: GE). GE HealthCare has been actively seeking avenues to enhance growth and sharpen its operational focus. In July of this year, the firm initiated a strategic review of its patient care solutions division. Activist investor Trian Fund Management, which played a pivotal role in orchestrating the GE breakup, has likewise raised its stake in GE HealthCare to nearly $200 million.
Sofie remains predominantly under the ownership of its founders and executives. Trilantic acquired a 25.8% interest in the company during 2024, a transaction that valued the firm at up to $550 million. A sale near $1 billion would represent a substantial premium over that previous valuation, intensifying pressure on GE HealthCare to deliver robust growth from the business.